FDA Issues Discussion Paper on Generative AI-Enabled Medical Devices

The paper seeks public input and aims to outline frameworks for risk assessment, premarket evaluation, and postmarket monitoring.

Matt MacKenzie

Aug. 18, 2026

Add Us On Google

Key Highlights

The FDA is seeking public input to develop a transparent regulatory approach for generative AI-enabled medical devices.
A two-axis risk assessment framework is proposed to evaluate potential risks associated with these advanced devices.
Premarket evaluation may involve competency assessments to ensure device safety and effectiveness before market entry.
Postmarket monitoring strategies are discussed to track device performance and address emerging safety concerns.
The initiative aims to balance innovation in medical technology with robust safeguards to protect patients and consumers.

The FDA has issued a discussion paper on the regulation of generative AI-enabled medical devices.

The agency is seeking feedback on risk assessment, premarket evaluation, postmarket monitoring, and other topics relevant to the regulation of GenAI-enabled medical devices. The paper is being led by the Digital Health Center of Excellence (DHCoE).

CDRH director Michelle Tarver said that inviting input from the public on this will launch a “transparent process to inform the development of an approach that safeguards patients and consumers, advances innovation, and serves as a potential model for regulators around the world.” GenAI-enabled devices may offer promise for advancing patient care, but there are definite risks involved.

The paper outlines a two-axis framework for risk assessment that could be used to inform regulatory expectations. It also discusses a potential approach to premarket evaluation built on the concept of competency assessment. Postmarket monitoring is also discussed.